Fintel reports that on January 9, 2026, Morgan Stanley initiated coverage of Monopar Therapeutics (NasdaqCM:MNPR) with a Overweight recommendation.
Analyst Price Forecast Suggests 81.65% Upside
As of December 21, 2025, the average one-year price target for Monopar Therapeutics is $114.00/share. The forecasts range from a low of $93.93 to a high of $136.50. The average price target represents an increase of 81.65% from its latest reported closing price of $62.76 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Monopar Therapeutics is 85MM. The projected annual non-GAAP EPS is -0.77.
What is the Fund Sentiment?
There are 112 funds or institutions reporting positions in Monopar Therapeutics. This is an increase of 11 owner(s) or 10.89% in the last quarter. Average portfolio weight of all funds dedicated to MNPR is 0.09%, an increase of 235.85%. Total shares owned by institutions increased in the last three months by 34.67% to 4,504K shares.
What are Other Shareholders Doing?
Janus Henderson Group holds 1,287K shares representing 19.26% ownership of the company. In its prior filing, the firm reported owning 1,172K shares , representing an increase of 8.93%. The firm decreased its portfolio allocation in MNPR by 9.13% over the last quarter.
Adage Capital Partners Gp, L.l.c. holds 659K shares representing 9.86% ownership of the company. In its prior filing, the firm reported owning 599K shares , representing an increase of 9.10%. The firm increased its portfolio allocation in MNPR by 136.03% over the last quarter.
Ra Capital Management holds 511K shares representing 7.65% ownership of the company. No change in the last quarter.
Wellington Management Group Llp holds 231K shares representing 3.46% ownership of the company.
Deerfield Management Company, L.p. holds 160K shares representing 2.39% ownership of the company.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
